Swanson Reed is a leading firm in the area of R&D tax credits and innovation incentives. We service a diverse range of clients from technology start-ups to billion dollar NASDAQ listed and Government Owned Corporations in the commercial aspects of research, development, management and technology transfer. Swanson Reed seeks to recruit an Executive Assistant to join their energetic team.
By providing support to Senior Managers your responsibilities will include:
High level administrative support
Organising business functions, projects and domestic/international travel arrangements
Assisting with WIP budget management and reporting
Facilitation and attendance of team meetings
Communicating with key stakeholders
You will also have the opportunity to get involved in ad hoc projects which will give you exposure to the broader business.
The successful candidate will have a demonstrated track record of success as an Executive Assistant, preferably within a professional services or financial services environment. You will have outstanding communication skills, demonstrate a proactive and results orientated approach and have strong planning and organisational abilities. Ideally you will have exposure to managing work in progress, timesheets and expenses. You will be driven, proactive and be able to make quick decisions and work autonomously
A self-starter with an inquisitive mind who demonstrates a committed and flexible approach complemented by exceptional relationship management skills will excel in this role.
The National Institute of Health (NIH) is investing $248.7 million in new technologies to address challenges associated with COVID-19 testing. NIH’s Rapid Acceleration of Diagnostics (RADx) initiative has awarded contracts to seven biomedical diagnostic companies to support a range of new lab-based and point-of-care tests that could significantly increase the number, [...]
Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancers and 60% of these have wild-type epidermal growth factor receptor (EGFR) mutations. [...]